Risk factors that may be driving the emergence of drug resistance in tuberculosis patients treated in Yangon, Myanmar

Background The majority of new tuberculosis cases emerging every year occur in low and middle-income countries where public health systems are often characterised by weak infrastructure and inadequate resources. This study investigates healthcare seeking behaviour, knowledge and treatment of tuberculosis patients in Myanmar—which is facing an acute drug-resistant tuberculosis epidemic—and identifies factors that may increase the risk of emergence of drug-resistant tuberculosis. Methods We randomly selected adult smear-positive pulmonary tuberculosis patients diagnosed between September 2014 and March 2015 at ten public township health centres in Yangon, the largest city in Myanmar. Data on patients’ healthcare seeking behaviour, treatment at the township health centres, co-morbidities and knowledge was collected through patient interviews and extraction from hospital records. A retrospective descriptive cross-sectional analysis was conducted. Results Of 404 TB patients selected to participate in the study, 11 had died since diagnosis, resulting in 393 patients being included in the final analysis. Results indicate that a high proportion of patients (16%; 95% CI = 13–20) did not have a treatment supporter assigned to improve adherence to medication, with men being more likely to have no treatment supporter assigned. Use of private healthcare providers was very common; 59% (54–64) and 30.3% (25.9–35.0) of patients reported first seeking care at private clinics and pharmacies respectively. We found that 8% (6–11) of tuberculosis patients had confirmed diabetes. Most patients had some knowledge about tuberculosis transmission and the consequences of missing treatment. However, 5% (3–8) stated that they miss taking tuberculosis medicines at least weekly, and patients with no knowledge of consequences of missing treatment were more likely to miss doses. Conclusions This study analysed healthcare seeking behaviour and treatment related practices of tuberculosis patients being managed under operational conditions in a fragile health system. Findings indicate that ensuring that treatment adherence support is arranged for all patients, monitoring of response to treatment among the high proportion of tuberculosis patients with diabetes and engagement with private healthcare providers could be strategies addressed to reduce the risk of emergence of drug-resistant tuberculosis.

[1]  L. Westerkamp,et al.  Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness , 2015, BMC Infectious Diseases.

[2]  R. Coker,et al.  How to hinder tuberculosis control: five easy steps , 2014, The Lancet.

[3]  Tuberculosis in Myanmar Progress , Plans and Challenges , 2012 .

[4]  A. Harries,et al.  The impact of diabetes on tuberculosis treatment outcomes: A systematic review , 2011, BMC medicine.

[5]  I. Hazarika Role of Private Sector in Providing Tuberculosis Care: Evidence from a Population-based Survey in India , 2011, Journal of global infectious diseases.

[6]  Philippe Glaziou,et al.  Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.

[7]  J. Caminero Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  S. Saw,et al.  Success and challenges of Public-Private Mix DOTS initiatives in Myanmar: a process evaluation for partnership approach of non-governmental organizations. , 2009 .

[9]  P. Garner,et al.  Directly observed therapy for treating tuberculosis. , 2015, The Cochrane database of systematic reviews.

[10]  M. Uplekar,et al.  Social franchising of TB care through private GPs in Myanmar: an assessment of treatment results, access, equity and financial protection. , 2007, Health policy and planning.

[11]  Ross Upshur,et al.  XDR-TB in South Africa: No Time for Denial or Complacency , 2007, PLoS medicine.

[12]  S. Ramaiah,et al.  Private health care in developing countries , 2002, BMJ : British Medical Journal.

[13]  S. Saw,et al.  Existing practices of general practitioners on diagnosis and treatment of tuberculosis in Yangon , 2002 .

[14]  Vikram Pathania,et al.  Private practitioners and public health: weak links in tuberculosis control , 2001, The Lancet.

[15]  G. Tomson,et al.  “Doi moi” and private pharmacies: a case study on dispensing and financial issues in Hanoi, Vietnam , 1999, European Journal of Clinical Pharmacology.

[16]  Y. Amdekar,et al.  Multidrug resistant tuberculosis. , 1998, Indian pediatrics.

[17]  M. Uplekar,et al.  Treatment of tuberculosis by private general practitioners in India. , 1991, Tubercle.

[18]  C. Dolea,et al.  World Health Organization , 1949, International Organization.